| Literature DB >> 26445876 |
Ryotaro Bouchi1, Takato Takeuchi2, Momoko Akihisa3, Norihiko Ohara4, Yujiro Nakano5, Rie Nishitani6, Masanori Murakami7, Tatsuya Fukuda8, Masamichi Fujita9, Isao Minami10, Hajime Izumiyama11,12, Koshi Hashimoto13,14, Takanobu Yoshimoto15, Yoshihiro Ogawa16,17.
Abstract
BACKGROUND: Abdominal visceral obesity has been reported to be associated with cardiovascular risks than body mass index, waist circumference, and abdominal subcutaneous fat. On the other hand, there is evidence that subcutaneous fat has a beneficial role against cardio-metabolic risks such as diabetes or dyslipidemia. However, little is known regarding the association between high visceral fat with low subcutaneous fat accumulation and the risk for atherosclerosis.Entities:
Mesh:
Year: 2015 PMID: 26445876 PMCID: PMC4597374 DOI: 10.1186/s12933-015-0302-4
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1The correlation between visceral fat area and subcutaneous fat area in patients with type 2 diabetes. SFA subcutaneous fat area (cm2), VFA visceral fat area (cm2)
Clinical data of patients with type 2 diabetes
| VFA (cm2) | <100 | ≥100 | p value* | ||
|---|---|---|---|---|---|
| SFA (cm2) | <100 (N = 34) | ≥100 (N = 39) | <100 (N = 11) | ≥100 (N = 64) | |
| VFA (cm2) | 56 ± 26 | 74 ± 21 | 149 ± 34 | 175 ± 52 | <0.001 |
| SFA (cm2) | 61 ± 23 | 157 ± 41 | 78 ± 16 | 149 ± 34 | <0.001 |
| VFA-to-SFA ratio | 1.00 ± 0.43 | 0.50 ± 0.20 | 1.98 ± 0.62 | 0.92 ± 0.33 | <0.001 |
| Age (years) | 70 ± 10 | 64 ± 11 | 72 ± 6 | 62 ± 12 | 0.001 |
| Gender (% male) | 77 | 18 | 100 | 59 | <0.001 |
| BMI (kg/m2) | 19.4 ± 2.1 | 23.2 ± 2.4 | 22.5 ± 1.8 | 27.0 ± 3.8 | <0.001 |
| SBP (mmHg) | 118 ± 15 | 115 ± 9 | 136 ± 13 | 129 ± 11 | <0.001 |
| DBP (mmHg) | 68 ± 11 | 66 ± 9 | 78 ± 15 | 75 ± 12 | <0.001 |
| Current smoker (%) | 0 | 5 | 18 | 11 | 0.111 |
| Duration of diabetes (years) | 4.9 (4.2–5.7) | 2.6 (2.2–3.2) | 3.8 (3.0–4.8) | 3.2 (3.1–3.3) | 0.120 |
| HbA1c (%) | 6.9 ± 1.0 | 6.7 ± 0.4 | 6.7 ± 0.4 | 7.4 ± 1.7 | 0.024 |
| Triglycerides (mmol/l) | 1.36 (1.15–1.61) | 1.01 (0.88–1.16) | 1.16 (0.79–1.69) | 1.67 (1.43–1.96) | 0.001 |
| HDL cholesterol (mmol/l) | 1.48 ± 0.52 | 1.50 ± 0.58 | 1.61 ± 0.42 | 1.52 ± 0.44 | 0.900 |
| LDL cholesterol (mmol/l) | 2.42 ± 0.72 | 2.80 ± 1.05 | 2.80 ± 0.75 | 2.95 ± 0.82 | 0.052 |
| Uric acid (μmol/l) | 282 ± 85 | 265 ± 82 | 395 ± 91 | 335 ± 58 | <0.001 |
| eGFR (ml/min/1.73 m2) | 76.8 ± 18.1 | 73.0 ± 21.5 | 62.3 ± 22.6 | 70.6 ± 23.4 | 0.250 |
| Log ACR (mg/g) | 24 (18–31) | 23 (15–35) | 25 (11–55) | 45 (31–68) | <0.001 |
| PDR (%) | 6 | 0 | 0 | 11 | 0.128 |
| AST (U/l) | 25 (23–27) | 21 (19–24) | 27 (22–34) | 25 (23–28) | 0.060 |
| ALT (U/l) | 21 (17–25) | 16 (14–17) | 21 (14–31) | 27 (23–31) | <0.001 |
| γ-GTP (U/l) | 26 (23–31) | 23 (21–25) | 64 (37–112) | 41 (29–59) | <0.001 |
| CIMT (mm) | 0.86 ± 0.17 | 0.88 ± 0.07 | 1.30 0.41 | 0.81 ± 0.17 | <0.001 |
Data are expressed as mean ± SD, geometric mean (95 % CI) or percentage
ALT alanine aminotransferase, AST asparatate aminotransferase, CIMT carotid intima media thickness, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, γ-GTP glutamyl transpeptidase, HDL high-density lipoprotein, LDL low-density lipoprotein, PDR proliferative diabetic retinopathy, SBP systolic blood pressure
* One-way ANOVA or Chi square test
Medications of patients with type 2 diabetes
| VFA (cm2) | <100 | ≥100 | p value* | ||
|---|---|---|---|---|---|
| SFA (cm2) | <100 (N = 34) | ≥100 (N = 39) | <100 (N = 11) | ≥100 (N = 34) | |
| OHA (%) | 41.2 | 33.3 | 54.5 | 54.7 | 0.164 |
| Sulfonylureas (%) | 25.0 | 0.0 | 12.5 | 22.4 | 0.055 |
| Biguanides (%) | 16.7 | 15.4 | 0.0 | 40.8 | 0.012 |
| Alpha-GIs (%) | 25.0 | 0.0 | 12.5 | 10.2 | 0.048 |
| TZDs (%) | 8.3 | 0.0 | 7.7 | 6.1 | 0.301 |
| DPP4 inhibitors (%) | 25.0 | 42.3 | 62.5 | 34.7 | 0.245 |
| Glinides (%) | 8.3 | 0.0 | 0.0 | 0.0 | 0.070 |
| GLP-1 agonists (%) | 0.0 | 0.0 | 0.0 | 2.0 | 0.754 |
| Insulin (%) | 41.2 | 38.5 | 18.2 | 35.9 | 0.575 |
| ACEIs (%) | 0.0 | 5.4 | 0.0 | 3.2 | 0.516 |
| ARBs (%) | 17.6 | 24.3 | 45.5 | 44.4 | 0.025 |
| CCBs (%) | 11.8 | 5.4 | 36.4 | 30.2 | 0.007 |
| Beta blockers (%) | 5.9 | 18.9 | 18.2 | 14.3 | 0.424 |
| Alpha blockers (%) | 0.0 | 5.4 | 0.0 | 1.6 | 0.383 |
| Diuretics (%) | 5.9 | 24.3 | 9.1 | 11.1 | 0.110 |
| Statins (%) | 11.8 | 16.2 | 0.0 | 34.9 | 0.007 |
| Fibrates (%) | 0.0 | 0.0 | 0.0 | 3.2 | 0.451 |
| UA-lowering agents | 0.0 | 10.8 | 9.1 | 6.3 | 0.289 |
| Anti-platelets (%) | 11.8 | 0.0 | 9.1 | 12.7 | 0.168 |
Data are expressed as percentage
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, DPP4 dipeptidyl peptidase-4, GI glycosidase inhibitor, GLP-1 glucagon-like peptide-1, OHA oral hypoglycemic agent, TZD thiazolidinedione, UA uric acid
* Chi square test
Linear regression analysis for risk factors of intima media thickness in patients with type 2 diabetes
| Standardized β | p values | |
|---|---|---|
| Univariates | ||
| SFA ≥ 100 cm2 and VFA < 100 cm2 [S(+)V(−)] | 0.032 | 0.813 |
| SFA < 100 cm2 and VFA ≥ 100 cm2 [S(−)V(+)] | 0.531 | <0.001 |
| SFA ≥ 100 cm2 and VFA ≥ 100 cm2 [S(+)V(+)] | −0.128 | 0.359 |
| Multivariates | ||
| SFA ≥ 100 cm2 and VFA < 100 cm2 [S(+)V(−)] | −0.100 | 0.386 |
| SFA < 100 cm2 and VFA ≥ 100 cm2 [S(−)V(+)] | 0.423 | <0.001 |
| SFA ≥ 100 cm2 and VFA ≥ 100 cm2 [S(+)V(+)] | −0.319 | 0.009 |
| Age | 0.575 | <0.001 |
| Urinary ACR | 0.299 | 0.001 |
| CCBs | −0.171 | 0.023 |
| Duration of diabetes | 0.156 | 0.049 |
Covariates; age, gender, history of cardiovascular disease, systolic blood pressure, duration of diabetes, current smoking, HbA1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, logarithmically transformed triglycerides, C-reactive protein, eGFR, albuminuria, the use of insulin, oral hypoglycemic agents, renin-angiotensin system blockers, calcium channel blockers and statins
ACR albumin-to-creatinine ratio, CCB calcium channel blocker, SFA subcutaneous fat area, VFA visceral fat area